Dyspnoea and pulmonary and/or peripheral congestion are the most frequent manifestations of acute heart failure (AHF) and are important targets for therapy. We have assessed changes in dyspnoea, their relationship with mortality, and the effects of the adenosine A1 receptor antagonist rolofylline on these endpoints in patients enrolled in the PROTECT trial.
Introduction
Dyspnoea and pulmonary and/or peripheral congestion are the main clinical manifestations of acute heart failure (AHF) and are important targets for therapy. Acute heart failure is associated with a poor prognosis with deaths or rehospitalizations occurring in 50% of the patients in the 3-6 months after discharge. 1 -3 An improvement in dyspnoea did not predict a reduction in deaths and rehospitalizations in most previous drug intervention trials, 4 -10 leading to concerns about the validity of dyspnoea as an endpoint, especially when considered alone. 11 This lack of association between the effects of treatment on dyspnoea and on outcomes, observed in previous studies, may have multiple causes. First, the severity of dyspnoea as a symptom leading to hospitalization may
The aim of this study is to analyse the clinical and prognostic significance of changes in symptoms, namely dyspnoea, in the patients enrolled in the PROTECT trial. With this purpose, we performed a post hoc analysis of two of the three components of the primary endpoint of the study, namely dyspnoea relief and worsening heart failure (WHF) at Day 7, as well as additional analyses of the effects of rolofylline on changes in dyspnoea up to Day 7 and on short-term (in-hospital, 14, and 30 days) outcomes.
Methods
Inclusion criteria and study design PROTECT was a multicentre, randomized, double-blind, placebocontrolled trial in patients hospitalized for AHF conducted in North America, Europe, Israel, and Argentina. A detailed description of the study design has been published previously. 26, 27 For entry, patients were required to have dyspnoea at rest or with minimal activity, signs, and symptoms of volume overload requiring intravenous (i.v.) loop diuretic therapy, impaired renal function (estimated creatinine clearance of 20 -80 mL/min by the Cockcroft-Gault equation corrected for weight in oedematous or obese subjects ≥100 kg), and elevated natriuretic peptide levels [brain natriuretic peptide (BNP) ≥500 pg/mL or N-terminal-pro-BNP (NT-proBNP) ≥2000 pg/mL]. Exclusion criteria are outlined in the design paper. 27 Our study fulfilled the requirements stated in the Declaration of Helsinki and it was approved by the Ethics Committees at each participating centre. Patients provided written informed consent.
Patients were randomized to receive rolofylline 30 mg administered as a daily 4 h infusion for 3 days or placebo in a double-blind manner according to a computer-generated randomization scheme; with a 2:1 rolofylline to placebo allocation. Heart failure signs (jugular venous pressure, rales, and oedema) and symptoms (dyspnoea and orthopnoea) were evaluated by a physician just prior to the initial study drug administration, daily through discharge on Day 6, and on Days 7 and 14. Patients' self-reported symptoms (dyspnoea and general well-being, each assessed utilizing a seven-point Likert scale of change compared with baseline) were recorded daily from Days 2 to 6 or to discharge, if earlier, and at Days 7 and 14. Assessments at Days 2 and 3 corresponded to measurements taken at 24 and 48 h from study drug initiation. Blood samples for measurements of serum creatinine, blood urea nitrogen, and uric acid were obtained daily. Electrolytes, glucose, and complete blood count were measured at baseline and Days 2, 7, and 14.
Follow-up evaluations at Days 7 and 14 included a physician assessment, interim history, laboratory tests as noted above, and adverse event evaluation. Adverse events were captured through Day 7; serious adverse events were recorded through Day 14. Patients were contacted by telephone to identify deaths and re-admissions up to Day 60 and to assess vital status at Day 180.
Endpoints in PROTECT
The primary and secondary endpoints of the PROTECT study are described in the design paper and have been recently reported. 26, 27 Briefly, the primary endpoint was an ordered composite endpoint according to which patients were classified as success, unchanged, or failure. Success was defined as patient-reported moderately or markedly better dyspnoea using a seven-point Likert scale at both 24 and 48 h after the initiation of study drug administration in the absence of any criterion for treatment failure. Failure included any of the following: death through Day 7, WHF or rehospitalization for HF through Day 7, or persistent renal impairment. Worsening heart failure was reported based on worsening signs and symptoms of HF with resulting intensification of i.v. therapy for HF or mechanical circulatory or ventilator support. Persistent renal impairment was defined as a serum creatinine increase of ≥0.3 mg/dL (26.5 mmol/L) from randomization to Day 7, confirmed at Day 14, or the initiation of haemofiltration or dialysis through Day 7.
Endpoints of the present analysis
The endpoints of the present analysis were changes in symptoms (i.e. dyspnoea relief and occurrence of WHF rate through Day 7 from randomization) and short-term (through Days 14 and 30) mortality rates.
Dyspnoea relief was defined according to the definition used for the primary endpoint of PROTECT, i.e. moderately or markedly better dyspnoea at both 24 and 48 h randomization. The criteria for WHF to Day 7 are defined above (see components of the primary endpoint). Cause-specific mortality was analysed according to the adjudications of the blinded Clinical Events Committee.
Statistical methods
Continuous variables are summarized as mean + standard deviation (SD), or as median and inter-quartile range (IQR). Statistical analyses were performed using SAS version 9.2. All analyses were performed by the intention-to-treat method. We used two-sided t-tests for statistical comparisons. A P-value of ,0.05 was considered as threshold for statistical significance. The Kaplan-Meier estimates of mortality rates are given. In-hospital mortality for patients who were still hospitalized at Day 30 was censored at 30 days. Hazard ratios (HRs) were estimated from the Cox regression models, odds ratios (OR) were estimated from logistic regression models, and mean differences 
Results

Patient characteristics and short-term follow-up
Complete evaluations of early dyspnoea changes were obtained in 1998 of 2033 patients enrolled in PROTECT. Thirty-five patients were excluded since they did not have full data on dyspnoea relief. Early dyspnoea relief, using the rigorous definition described above, occurred in only 49.8% of the patients.
Worsening heart failure through Day 7 occurred in 10.7% of the patients; 3.6 and 4.8% of the patients died by Days 14 and 30, respectively. Baseline characteristics of patients with and without dyspnoea relief are presented in Table 1 . Patients with dyspnoea relief had lower NYHA class prior to admission, lower creatinine, and slightly higher blood pressure. They were treated with less i.v. furosemide, inotropes, or vasodilators and were more likely to receive angiotensin-converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs) and b-blockers at discharge or up to Day 7. Patients who experienced dyspnoea relief had a greater average decline in body weight over Days 2-4 after enrolment [mean difference (95% CI), 20.48 (20.27, 20.70 ) kg], and this difference was evident across all subgroups tested ( Table 2) . Baseline characteristics of patients who survived to Days 14 and 30 are depicted in Table 3 .
Prognostic significance of early changes in symptoms
Patients with early dyspnoea relief had numerically lower mortality at both 14 and 30 days and the estimated magnitude of the association was similar within subgroups defined by baseline variables, including variables related with the severity of HF before hospitalization (NYHA class, serum creatinine or creatinine clearance, systolic blood pressure, blood levels of natriuretic peptides; Table 4 ). Of note, patients with dyspnoea relief had lower NYHA class prior to admission, lower creatinine, and slightly higher blood pressure. In addition, they were more likely to receive ACE-inhibitors or ARBs and b-blockers at discharge or up to Day 7. These suggest that patients with dyspnoea relief had lower severity of HF. However, the association between dyspnoea relief and better survival, irrespective of the study group, remained significant also after adjustment for age, NYHA class, baseline BNP level, serum creatinine, serum sodium, and blood pressure at multivariable analysis ( with the absence of this event, and this association was also consistent across all subgroups examined ( Table 6 ).
Effects of rolofylline administration
Compared with placebo, rolofylline administration was associated with greater weight loss. At 72 h, the mean (95% CI) body weight decrease in patients assigned to placebo was 22.55 (22.79, Table 7) . This difference persisted, although reduced in magnitude, to Day 14 ( Figure 1) . Similar results were found with respect to the assessment of NYHA class with a lower proportion of patients in NYHA class IV in the rolofylline group commencing with Day 2 up to Day 14 ( Figure 2) . Overall, the proportion of patients meeting criteria for WHF was similar with rolofylline (10.5%) and placebo [11 defined subgroups based on NYHA class before hospitalization, serum creatinine, or creatinine clearance at baseline were found ( Table 7) . The duration of hospital stay was numerically shorter with rolofylline, compared with placebo [mean + SD, 14.5 + 20.8 vs. 16 .0 + 23.8 days; treatment difference (95% CI) 21.54 (23.56, 0.48) days] ( Table 7) . Days 14 and 30 and in-hospital mortality are presented in Figure 3 . Hazard ratios (95% CI) for all-cause mortality for rolofylline vs. placebo at Days 14 and 30 were 0.80 (0.50, 1.29) and 0.86 (0.56, 1.27), respectively. These results were largely driven by mortality due to HF [30-day HF mortality, HR (95% CI): 0.65 (0.38, 1.1); Figure 3 ]. Overall mortality to Day 180 was not different between placebo and rolofylline (17.6 vs. 18%, respectively), but HF mortality was numerically lower also at Day 180 (8.3 vs. 10.8%).
Discussion
In the PROTECT study, about half of the patients did not achieve marked or moderate relief of dyspnoea within 24 h, and 10.7% developed WHF during the first week of hospitalization. Lack of dyspnoea relief and WHF were each associated with increased mortality at 14 and 30 days and this relation persisted after adjustment for other variables known to affect outcomes in patients with AHF. Rolofylline administration was associated with a greater decline in body weight, more patients obtaining early dyspnoea relief and a non-significant, although numerically lower, mortality in the first month, which was mostly due to fewer deaths caused by HF.
The results of the present study are consistent with those of the previously published PROTECT Pilot trial. Favourable effects of rolofylline on dyspnoea and a relation between dyspnoea relief and short-term outcomes were shown also in that study. 25, 28 However, the lack of effects of rolofylline on serum creatinine levels and its untoward central nervous system effects became evident only in the much larger main PROTECT trial. 26 These discrepancies emphasize the need to perform large multicentre trials in order to confirm favourable findings from smaller pilot studies and evaluate drug safety.
11
Clinical significance of dyspnoea relief Dyspnoea relief was a main component of the primary endpoint in PROTECT. This variable has been criticized as an endpoint because it is subjective, difficult to measure, and can be expected to improve in the control group because of concomitant treatments. 2, 11, 29 However, it is the main cause of hospitalization for the patients with AHF, has been used as primary endpoint in virtually all AHF trials, 6 -9,25,29 and has shown differences between active treatment and placebo in most of them. 6 -8 In the PROTECT study, the proportion of patients who achieved moderate or marked dyspnoea relief at 24 and 48 h was low (49.8%). This value was, however, similar to that found in the pilot study of PROTECT (54%) 25 and to that shown by an observational study regarding early changes in dyspnoea after an admission for AHF. 30, 31 Our proportion of patients improving was, however, lower compared with previous studies where 65% of the patients assigned to placebo showed an early improvement of dyspnoea. 6, 7 This may relate to the definition of dyspnoea relief (i.e. a moderate to marked better dyspnoea at both Days 2 and 3) as well as the inclusion criteria of the study, including signs of fluid overload, need of i.v. diuretic therapy, underlying renal dysfunction, and, most importantly, elevated natriuretic peptides plasma levels, probably excluding patients with non-cardiac causes of dyspnoea and with mild HF. 32 Our results suggest that current AHF therapy is suboptimal not only with respect to outcomes but also with respect to symptom relief. 30, 31 In the present study, dyspnoea relief was associated with lower all-cause mortality at both 14 and 30 days. However, only a few baseline variables (NYHA class before admission, renal impairment) were different between patients with and without dyspnoea relief, underlining our limited understanding of the pathophysiology of AHF and of, specifically, pulmonary congestion. 12, 33 Measurement of left ventricular ejection fraction could have increased the predictive value of the model. This variable was not assessed and reported systematically in PROTECT as the drug was perceived to act trough effects on fluid retention and renal protection.
Effects of rolofylline
In the PROTECT study, early dyspnoea relief was associated with a greater decline in body weight and rolofylline induced more weight loss and dyspnoea relief, compared with placebo. These effects are consistent with rolofylline's mild diuretic action and confirm data from previous studies with adenosine A1 receptor antagonists. 23, 24 These agents inhibit sodium reuptake in the proximal tubule and may therefore enhance the effects of loop diuretics. Although the effects of rolofylline on dyspnoea may be deemed as small [OR (95% CI): 1.30 (1.08, 1.57) for achievement of dyspnoea relief with rolofylline vs. placebo], they are of larger magnitude than those reported with other drugs currently approved for the treatment of AHF in many countries 6 -8 as well as with those achieved by a 2.5-fold increase in furosemide dose in the Diuretic Optimization Strategies Evaluation (DOSE) Study. 34 In that trial, the administration of higher doses of furosemide was associated with a slight improvement in dyspnoea relief and weight loss and with a Early dyspnoea relief in acute heart failure transient increase in creatinine (seemingly larger than that reported in PROTECT). Although a head-to-head comparison of rolofylline and high-dose furosemide was not performed, these data show that enhanced diuresis (either by more i.v. furosemide or rolofylline), in patients with fluid overload and high natriuretic peptide levels, can have some beneficial effects on symptoms, even in the absence of any favourable effect on kidney function or while leading to some mostly transient creatinine increases. In contrast to the results from studies with the treatment of chronic HF 1, 3 as well as with coronary revascularization in patients with acute myocardial infarction, the non-significant numerically smaller number of early deaths in the rolofylline-vs. placebotreated patients did not persist after 30 days, suggesting that there it may be a chance finding. However, the fact that these effects were mostly driven by disease-specific (i.e. HF) mortality, while non-disease-specific mortality was not affected, increases the likelihood that they represent a real effect. Secondly, patients admitted for AHF are older and have substantial background morbidity. Such non-cardiovascular or non-HF co-morbidities have a strong impact on prognosis, 1, 16, 35 but HF-specific therapies may have limited effectiveness on them. Indeed, numerically lower HF mortality was observed at 180 days from enrolment, but the effect on all-cause mortality was diluted by death from other causes. Thirdly, episodes of AHF may represent the manifestation of advanced to end-stage HF, a condition in which medical treatment is less likely to improve effectively long-term prognosis. 36 Finally, it is likely that an intervention with favourable effects needs to be repeated rather than administered only once in the context of a randomized trial, to be effective. These observations suggest that a short-term treatment associated with early symptoms improvement is more likely to have an impact on short-term outcomes, whereas long-term outcomes are more dependent on co-morbidities and mechanisms causing disease progression. Most importantly, the present analyses suggest that short-term outcomes may be strongly related with early dyspnoea relief and that different from previous trials, 5, 7 symptoms' improvement may be associated with a neutral, if not better, short-term outcome.
Limitations
Although the dyspnoea relief endpoints examined in the present manuscript were pre-defined as components of the primary endpoint, their separate analysis was not pre-defined in the PROTECT programme. PROTECT was not powered to detect a modest effect of rolofylline on mortality and its effects on shortterm mortality constituted a post hoc analysis. Hence, these results cannot be regarded as definitive. With respect of subgroup analysis, baseline serum creatinine, estimated creatinine clearance, and NYHA class were identified as of interest a priori and included in the subgroup analysis for the primary and secondary endpoints of PROTECT. 26 They were included also in the present study, although their relation with short-term outcomes is a post hoc analysis. As no differences between rolofylline and placebo were present with respect to baseline characteristics, no adjustment for baseline characteristics by multivariable analysis was performed in the present analysis. An assessment of the clinical significance of symptoms relief and short-term outcomes would need adjustment for baseline data. Severity of symptoms at baseline may influence their changes after treatment. 30, 31 Although it is possible that some patients did not report improvement because their symptoms were not particularly severe at baseline, the selection criteria for the study favoured inclusion of more severe patients. Patients who did not have dyspnoea relief had more high-risk features and had three to four times higher mortality, suggesting that the lack of dyspnoea relief occurred for the most part in sicker patients who did not improve with current available therapies. Unfortunately, no data regarding the severity of symptoms at baseline were collected in PROTECT except for NYHA class as dyspnoea was measured using the Likert scale to compare the severity of breathlessness with baseline values.
Conclusions
Using objective inclusion criteria based on plasma natriuretic peptides, marked or moderate dyspnoea relief at 24 and 48 h occurred in slightly ,50% of patients in the PROTECT study. Early dyspnoea relief was associated with lower short-term (30 days) mortality.
